Metraipolis › archive › dc_d6e4ffc830bf

Lenvatinib after progression on pemigatinib and futibatinib in FGFR2 fusion-positive biliary tract cancer with an acquired kinase point mutation — Europe PMC PMID:41032264

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41032264
DOI
10.1093/oncolo/oyaf322
License (as archived)
solo-consultazione
Archived
2026-11-09T16:19:45.598Z
SHA-256 of the archived text
d01dc29191dfc4ce714c10111c58125a3dc0605c1bb450fc04d6e70d3721d3cb
Stable URL of this page
https://metraipolis.com/documento/dc_d6e4ffc830bf

How to cite

Lenvatinib after progression on pemigatinib and futibatinib in FGFR2 fusion-positive biliary tract cancer with an acquired kinase point mutation — Europe PMC PMID:41032264 — Europe PMC (en), https://europepmc.org/article/MED/41032264 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_d6e4ffc830bf (Metraipolis archive dc_d6e4ffc830bf, sha256 d01dc29191dfc4ce714c10111c58125a3dc0605c1bb450fc04d6e70d3721d3cb)
BibTeX
@misc{dcd6e4ffc830bf,
  title = {Lenvatinib after progression on pemigatinib and futibatinib in FGFR2 fusion-positive biliary tract cancer with an acquired kinase point mutation — Europe PMC PMID:41032264},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41032264},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_d6e4ffc830bf; sha256 d01dc29191dfc4ce714c10111c58125a3dc0605c1bb450fc04d6e70d3721d3cb},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41032264. Agents can read the archived copy with the MCP tool read_document.